PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Key Highlights
- ➤Q3 revenue $98.3 million, up 18% year over year
- ➤U.S. procedures exceeded 13,400, increasing approximately 22% year over year
- ➤Net loss widened to $26.5 million from $21.4 million
- ➤2026 revenue guidance reaffirmed at $390 million-$410 million
- ➤2026 adjusted EBITDA loss guidance reaffirmed at $30 million-$35 million
Expert Statements
Larry Wood, Chief Executive Officer of PROCEPT BioRobotics
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan.”
Larry Wood, Chief Executive Officer of PROCEPT BioRobotics
“Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027.”
Larry Wood, Chief Executive Officer of PROCEPT BioRobotics
“We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”
Larry Wood, Chief Executive Officer of PROCEPT BioRobotics
“This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics(®) Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan,” said Larry Wood, Chief Executive Officer. “Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”
Get started
Create a free account to read the full story.